-
公开(公告)号：US20240245673A1
公开(公告)日：2024-07-25
申请号：US18532424
申请日：2023-12-07
Applicant: Pfizer Inc.
Inventor： James Matthew Frick , Michelle Renee Garnsey , Brian Stephen Gerstenberger , Xinjun Hou , Magdalena Korczynska , Alpha Albert Lee , Luong Tien Nguyen , Usa Reilly , Matthew Christopher Robinson , Alexandria Paige Taylor , Thomas Reynold Vargo , Lei Zhang
IPC: A61K31/4709 , A61K31/415 , A61K31/4178 , A61K31/4192 , A61K31/427 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D207/34 , C07D215/38 , C07D231/12 , C07D249/06 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/10 , C07D487/04 , C07D487/08 , C07D495/04
CPC classification number: A61K31/4709 , A61K31/415 , A61K31/4178 , A61K31/4192 , A61K31/427 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D207/34 , C07D215/38 , C07D231/12 , C07D249/06 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/10 , C07D487/04 , C07D487/08 , C07D495/04
Abstract: The invention relates to compounds of Formula (I)
and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may inhibit the activity of papain-like protease (PLpro) and may be useful in the treatment of viral infections, in particular viral infections associated with PLpro activity and/or expression such as coronaviruses infections.-
公开(公告)号：US20240238425A1
公开(公告)日：2024-07-18
申请号：US18541015
申请日：2023-12-15
Applicant: Pfizer Inc.
Inventor： Jan Antoinette Cusi Romero Adams , Yotam Ashkenazi , Matthew Frank Brown , Jason Kenneth Dutra , Michelle Renee Garnsey , Xinjun Hou , Jisun Lee , Yajing Lian , Deane Milford Nason, II , Steven Victor O'Neil , Amanda Brooke Pecora , Alistair Dean Richardson , Matthew Forrest Sammons , Yang Wang , Ann Sorrentino Wright , Jun Xiao , Lei Zhang , Liying Zhang
Abstract: Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide-containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
-
公开(公告)号：US11643412B2
公开(公告)日：2023-05-09
申请号：US17341877
申请日：2021-06-08
Applicant: Pfizer Inc.
Inventor： Christopher Ryan Butler , Michelle Renee Garnsey , Kevin Alexander Ogilvie , Jana Polivkova , Matthew Forrest Sammons , Aaron Christopher Smith , Qingyi Yang
IPC: C07D471/20 , C07D519/00 , A61K31/438 , A61P1/08 , A61P3/04 , A61P19/00 , A61P21/00 , A61P29/00
CPC classification number: C07D471/20 , C07D519/00 , C07B2200/13
Abstract: Described herein are compounds of Formula I:
and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.-
公开(公告)号：US11065249B2
公开(公告)日：2021-07-20
申请号：US17090619
申请日：2020-11-05
Applicant: Pfizer Inc.
Inventor： David James Edmonds , Kevin James Filipski , Kentaro Futatsugi , Michelle Renee Garnsey , Jack Chang Hung Lee , Daniel Jonathan Smaltz
IPC: A61K31/506 , A61P3/06 , A61K31/155 , A61K31/4545 , A61K31/4985 , A61K31/7048 , A61K45/06 , C07D401/14
Abstract: Described herein are compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
-
公开(公告)号：US11471458B2
公开(公告)日：2022-10-18
申请号：US17062982
申请日：2020-10-05
Applicant: Pfizer Inc.
Inventor： David James Edmonds , Kevin James Filipski , Kentaro Futatsugi , Michelle Renee Garnsey , Jack Chang Hung Lee , Daniel Jonathan Smaltz
IPC: A61K31/506 , A61P3/06 , A61K31/155 , A61K31/4545 , C07D401/14 , A61K31/4985 , A61K31/7048 , A61K45/06
Abstract: Described herein are compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
-
Patent Agency Ranking
公开(公告)号：US20210100798A1
公开(公告)日：2021-04-08
申请号：US17090619
申请日：2020-11-05
Applicant: Pfizer Inc.
Inventor： David James Edmonds , Kevin James Filipski , Kentaro Futatsugi , Michelle Renee Garnsey , Jack Chang Hung Lee , Daniel Jonathan Smaltz
IPC: A61K31/506 , A61K31/4545 , A61K31/155 , A61K31/7048 , A61K31/4985 , A61P3/06 , C07D401/14 , A61K45/06
Abstract: Described herein are compounds of Formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
-
公开(公告)号：US20210100796A1
公开(公告)日：2021-04-08
申请号：US17062982
申请日：2020-10-05
Applicant: Pfizer Inc.
Inventor： David James Edmonds , Kevin James Filipski , Kentaro Futatsugi , Michelle Renee Garnsey , Jack Chang Hung Lee , Daniel Jonathan Smaltz
IPC: A61K31/506 , C07D401/14 , A61K45/06 , A61P3/06 , A61K31/155 , A61K31/4985 , A61K31/7048 , A61K31/4545
Abstract: Described herein are compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
-
公开(公告)号：US20250129048A1
公开(公告)日：2025-04-24
申请号：US18713747
申请日：2022-12-05
Applicant: Pfizer Inc.
Inventor： Michelle Renee Garnsey , David Andrew Griffith , Christopher John Helal , Daniel Wei-Shung Kung , Yajing Lian , Kevin Alexander Ogilvie , Jana Polivkova , Brian Raymer , Matthew Forrest Sammons , Aaron Christopher Smith , Qingyi Yang
IPC: C07D401/14 , A61K31/4439 , A61K31/444 , A61K31/506 , C07D413/14 , C07D471/04 , C07D498/04
Abstract: Described herein are compounds of Formula I: I and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R7, RF, t1, Y1, and Y2 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
-
公开(公告)号：US12187727B2
公开(公告)日：2025-01-07
申请号：US18162052
申请日：2023-01-31
Applicant: Pfizer Inc.
Inventor： Christopher Ryan Butler , Michelle Renee Garnsey , Kevin Alexander Ogilvie , Jana Polivkova , Matthew Forrest Sammons , Aaron Christopher Smith , Qingyi Yang
IPC: A61K31/438 , A61P1/08 , A61P3/04 , A61P19/00 , A61P21/00 , A61P29/00 , C07D471/20 , C07D519/00
Abstract: Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I: or their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein. Such conditions, diseases, or disorders include cachexia, anorexia, or anorexia nervosa.
-
公开(公告)号：US20240150334A1
公开(公告)日：2024-05-09
申请号：US18482129
申请日：2023-10-06
Applicant: Pfizer Inc.
Inventor： Jan Antoinette Cusi Romero Adams , Bruce Michael Bechle , Jason Kenneth Dutra , Michelle Renee Garnsey , Xinjun Hou , Jisun Lee , Deane Milford Nason, II , Steven Victor O'Neil , Danica Antonia Rankic , Yang Wang , Ann Sorrentino Wright , Lei Zhang , Liying Zhang , David James Edmonds
IPC: C07D413/04 , C07D231/56 , C07D263/56 , C07D401/04 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D491/048 , C07D498/04 , C07D513/04
CPC classification number: C07D413/04 , C07D231/56 , C07D263/56 , C07D401/04 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D491/048 , C07D498/04 , C07D513/04
Abstract: Described herein are compounds of Formula I,
wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD and NASH.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.019 seconds)
